Last reviewed · How we verify

NCT07205068

Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure

Recruiting now NA Last updated 3 October 2025
What this trial tests

NA trial testing Shockwave M5 IVL Catheter in Aortic Stenosis in 100 participants. Currently enrolling.

Timeline
4 October 2025
Primary endpoint
4 November 2026
4 November 2026

Quick facts

Lead sponsorUniversity of Tennessee Graduate School of Medicine
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date4 October 2025
Primary completion4 November 2026
Estimated completion4 November 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Tennessee Graduate School of Medicine

Who can join

18 and older, any sex, with Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to observe reduced access site complications in patients with heavily calcified common femoral arteries requiring Transcatheter Aortic Valve Replacement (TAVR)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other University of Tennessee Graduate School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07205068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing